Cloud-clone
SKU:PAA751Ra01
Polyclonal Antibody to Programmed Cell Death Protein 1 (PD1)
Polyclonal Antibody to Programmed Cell Death Protein 1 (PD1)
Couldn't load pickup availability
Western blotting: 0.5-2µg/mL;
;Immunohistochemistry: 5-20µg/mL;
;Immunocytochemistry: 5-20µg/mL;
;Optimal working dilutions must be determined by end user.
Product No.
PAA751Ra01
Organism Species
Rattus norvegicus (Rat).
Source
Polyclonal antibody preparation
Host
Rabbit
Potency
n/a
Ig Type
IgG
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Label
None
Immunogen
RPA751Ra01-Recombinant Programmed Cell Death Protein 1 (PD1)
Buffer Formulation
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Traits
Liquid
Concentration
0.75mg/ml
Organism Species More
Mus musculus (Mouse)
Applications
WB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a rabbit polyclonal antibody raised against PD1. It has been selected for its ability to recognize PD1 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.2-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
| Magazine | Citations |
| Oncotarget | Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. pubmed:28545019 |
| CyberLeninka | Потенциальные биомаркеры эффективности терапии ниволумабом при метастатическом почечно-клеточном раке : |
| АНАЛИЗ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ПОЧКИ, ПОЛУЧАВШИХ АНТИ-PD-1‑ТЕРАПИЮ В РАМКАХ ПРОГРАММЫ … | |
| International Journal of Molecular Sciences | Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity Pubmed: 30699956 |
| PLoS One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated … Pubmed: 30807610 |
| Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study Pubmed: 32085544 |
| Catalog No. | Related products for research use of Rattus norvegicus (Rat) Organism species | Applications (RESEARCH USE ONLY!) |
| RPA751Ra01 | Recombinant Programmed Cell Death Protein 1 (PD1) | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA751Ra01 | Polyclonal Antibody to Programmed Cell Death Protein 1 (PD1) | WB; IHC; ICC; IP. |
Share
